Search

Your search for "adtx" returned the following results.
Filter Results:
InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) to Host Fireside Chat on Feb. 21 to Discuss Key Corporate Developments

February 13, 2025

Aditxt (NASDAQ: ADTX), a social innovation platform focused on advancing health innovations, will host a virtual Fireside Chat on Feb. 21, 2025, at 11:30 a.m. ET. CEO Amro Albanna will provide updates on the company’s subsidiaries, potential transactions, and pipeline advancements. The discussion will highlight Adimune, Inc.’s progress in autoimmunity treatments, including Type 1 Diabetes […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Explores IPO for Pearsanta to Advance Early Cancer Detection

January 13, 2025

Aditxt (NASDAQ: ADTX) a social innovation platform dedicated to advancing health innovations, announced its Board of Directors has authorized management to explore an initial public offering (“IPO”) for its subsidiary, Pearsanta, Inc., in 2025. Pearsanta, a precision diagnostics company leveraging its proprietary Mitomic® Technology platform for early cancer detection, aims to use the IPO proceeds […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Advances ADI-100 Gene Therapy Toward Human Trials

December 12, 2024

Aditxt (NASDAQ: ADTX) announced that its subsidiary, Adimune, Inc., has completed all preclinical efficacy and safety studies for ADI-100, an innovative antigen-specific gene therapy for autoimmune diseases such as Type 1 Diabetes, Psoriasis, and Stiff-Person Syndrome. Preclinical results demonstrated ADI-100’s ability to restore immune tolerance without impairing the immune system’s infection or tumor-fighting capabilities, showing […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Updates Shareholders on Equity Issuance and Shift to Debt Financing Strategy

November 8, 2024

Aditxt (NASDAQ: ADTX) provided shareholders with an update on its capital structure, disclosing details on shares issued through its Equity Line of Credit (“ELOC”) and At-the-Market (“ATM”) facility since activation. As of Nov. 7, 2024, Aditxt has sold approximately 11.9 million shares, representing 8% of the total 153 million shares traded since the ELOC and […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Acquisition of Appili Therapeutics Moves Forward with Overwhelming Shareholder Approval

November 7, 2024

Aditxt (NASDAQ: ADTX) announced a significant advancement in its acquisition of Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF), as Appili shareholders voted overwhelmingly in favor of the proposed plan for Aditxt to acquire all Class A common shares of Appili. This positive shareholder response marks a key step in Aditxt’s strategy to expand its health […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Gains Support for Evofem Merger as Voting Agreements Secure Favorable Votes

November 6, 2024

Aditxt (NASDAQ: ADTX) announced today that its acquisition target, Evofem Biosciences, Inc. (OTCQB: EVFM), has secured voting agreements from key investors, solidifying their commitment to vote in favor of the upcoming merger proposal at Evofem’s Special Meeting of Stockholders. This move advances Aditxt’s planned acquisition to establish a stronghold in women’s health through Evofem. Aditxt’s […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) to Hold CEO-Led Update and Q&A Session Covering Company Developments

October 31, 2024

Aditxt (NASDAQ: ADTX) will host a live update and Q&A session with CEO Amro Albanna on Friday, Nov. 1, 2024, at 11:30 a.m. ET. The session will offer stakeholders insights into the company’s current initiatives, provide transaction and Nasdaq compliance updates, and include a Q&A segment addressing pre-submitted questions from investors and the public. To […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Strengthens Leadership with Appointment of Governance Expert Sylvia Hermina to Board

October 29, 2024

Aditxt (NASDAQ: ADTX) has appointed Sylvia Hermina to its Board of Directors, adding over 20 years of expertise in corporate governance, M&A, and shareholder relations to its leadership. As a Senior VP at Kingsdale Advisors, Hermina has played a key role in the firm’s U.S. expansion and strategic M&A initiatives. Aditxt CEO Amro Albanna highlighted […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Moves Closer to Evofem Acquisition with Final Investment Milestone

October 28, 2024

Aditxt (NASDAQ: ADTX) has completed a key milestone toward its acquisition of Evofem Biosciences, Inc. (OTCQB: EVFM) by purchasing $2.28 million in Evofem Series F-1 convertible preferred stock, as stipulated under their Amended and Restated Merger Agreement. This investment represents Aditxt’s final funding commitment before the merger, where Evofem, known for women’s health innovations, would […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Hosts Virtual Fireside Chat to Discuss Evofem Acquisition and Future Strategic Plans

October 21, 2024

Aditxt (NASDAQ: ADTX) announced a virtual fireside chat on Oct. 28, 2024, featuring Aditxt CEO Amro Albanna and Evofem Biosciences CEO Saundra Pelletier, moderated by Dr. Drew Pinsky. The discussion will provide updates on Aditxt’s acquisition of Evofem, post-acquisition strategies, and the companies’ plans to enhance women’s health care solutions. Key topics include Evofem’s FDA-approved […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Announces Acquisition Target Plans Special Meeting of Shareholders to Obtain Transaction Approval

October 10, 2024

Aditxt (NASDAQ: ADTX), an innovation platform dedicated to accelerating promising health innovations, is reporting that Appili Therapeutics Inc. (TSX: APLI) (OTC: APLIF) has begun mailing its management information circular related to the company’s special meeting of shareholders, which is scheduled for next month. According to the announcement, the meeting will be held virtually on Nov. 6, […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Schedules Stakeholder Update, Q&A Session with CEO

October 9, 2024

Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, today announced that Amro Albanna, Co-Founder, Chairman, and CEO of the company, will host a stakeholder update and Q&A session on Friday, October 11, 2024, at 11:30 a.m. EDT. The session will cover the company’s current position and progress regarding the […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt (NASDAQ: ADTX), Evofem Announce Completion of Third Parent Equity Investment Under Amended Merger Agreement

October 8, 2024

Aditxt (NASDAQ: ADTX), an innovation platform dedicated to accelerating promising health innovations, and its acquisition target Evofem Biosciences (OTCQB: EVFM), a women’s health company, have completed the Third Parent Equity Investment under its Amended and Restated Merger Agreement. According to the announcement, this strengthens the strategic and collaborative relationship between the two companies, which share a […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt (NASDAQ: ADTX) Releases Shareholder Update, Plans for Remainder of 2024

October 3, 2024

Aditxt (NASDAQ: ADTX), an innovation platform dedicated to accelerating promising health innovations, is reporting to shareholders on plans for the 2024 year end. Highlights of the report include news about its two acquisition targets: Evofem Biosciences (OTCQB: EVFM) has reported $7.8 million in revenue for the first six months of 2024, while Appili Therapeutics Inc. (TSX: […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt (NASDAQ: ADTX) Acquisition Target Files Preliminary Proxy Seeking Stockholder Approval

September 24, 2024

Aditxt (NASDAQ: ADTX), an innovation platform dedicated to accelerating promising health innovations, has reported that its acquisition target, Evofem Biosciences (OTCQB: EVFM), a women’s health company, has filed a preliminary proxy. The proxy is seeking stockholder approval of transactions outlined under the Amended and Restated Merger Agreement with Aditxt and Adifem Inc., a wholly owned subsidiary of […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt (NASDAQ: ADTX) Subsidiary Signs Agreement with Evofem Biosciences Inc. (OTCQB: EVFM) Involving Unique Endometriosis Diagnostic Test

September 20, 2024

Aditxt (NASDAQ: ADTX), an innovation platform dedicated to accelerating promising health innovations, and its majority-owned subsidiary, Pearsanta Inc., have signed a market development collaboration agreement with Evofem Biosciences (OTCQB: EVFM), a women’s health company. According to the announcement, the agreement involves Pearsanta’s blood-based diagnostic test for endometriosis, which affects an estimated 190 million women globally. The […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Enters into Second Amendment to Amended and Restated Merger Agreement with Evofem

September 9, 2024

Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, and Evofem Biosciences Inc., a health pioneer commercializing innovative products to address unmet needs in women’s sexual and reproductive health, today announced the signing of the Second Amendment to the Amended and Restated Agreement and Plan of Merger, under which Aditxt […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Seeks Grant Funding to Advance Early Detection, Management of Prostate Cancer

September 4, 2024

Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, today announced that its subsidiary, Pearsanta, Inc., has submitted a grant application to the Prostate Cancer Research Program (“PCRP”) under the Department of Defense (“DoD”) Implementation Science Award funding mechanism. Pearsanta is seeking $2 million in non-dilutive funding to advance the […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt (NASDAQ: ADTX) Announces Participation at H.C. Wainwright 26th Annual Global Investment Conference

August 29, 2024

Aditxt (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing and deploying promising health innovations, will be participating in next month’s H.C. Wainwright 26th Annual Global Investment Conference. The conference is scheduled for Sept. 9–11, 2024, in New York City. According to the announcement, Aditxt cofounder, CEO and chair Amro Albanna will virtually present at the […]

InvestorNewsBreaks

InvestorNewsBreaks – Evofem Biosciences Inc. (EVFM) Subsidiary Appoints Industry Veteran as Subsidiary President

August 26, 2024

Aditxt (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing and deploying promising health innovations, has announced a new president for its majority-owned subsidiary, Pearsanta Inc. According to the announcement, Christoper Mitton has been named president of the subsidiary, which focuses on precision health. Mitton has an impressive career of leadership in the medical diagnostics space […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX), Appili Therapeutics (TSX: APLI) (OTC: APLIF) Enter Third Amending Agreement

August 21, 2024

Aditxt (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing and deploying promising health innovations, has entered into a third amending agreement with Appili Therapeutics Inc. (TSX: APLI) (OTC: APLIF), a biopharmaceutical company focused on developing innovative treatments and vaccines to combat some of the most challenging infectious diseases and potential bioterrorism threats. According to the […]

InvestorNewsBreaks

InvestorNewsBreaks – Evofem Biosciences Inc. (EVFM) Releases Second-Quarter 2024 Financial Results, Company Update

August 14, 2024

Evofem Biosciences (OTCQB: EVFM) is reporting on its financial results and corporate update for Q2 2024; the report also included a report on the first half of 2024. Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, entered into a merger agreement with Evofem last year; the agreement was amended and […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Releases Report on Annual Shareholders’ Meeting Activity

August 13, 2024

Aditxt (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing and deploying promising innovations, is reporting on the results of its recent annual shareholders’ meeting. According to the announcement, all nine proposed agenda items were successfully passed. Those proposals include the election of directors, the ratification of auditors, and the issuing of shares for Series B-1 […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Enters into $1.2M Registered Direct Offering Agreement

August 9, 2024

Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, has entered into a securities purchase agreement with certain institutional investors. The agreement outlines a registered direct offering for the purchase and sale of 1,130,189 shares of common stock or common stock equivalents for $1.06 per […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Submits Proposal to CDMRP for Ovarian Cancer Detection Research Award

August 7, 2024

Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, and its subsidiary, Pearsanta Inc., has submitted a proposal for the Clinical Trial Translational Endpoints Research Award to the Congressionally Directed Medical Research Programs (“CDMRP”) of the Department of Defense. According to the announcement, the proposal is designed to validate a novel […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX), Appili Therapeutics Sign Second Amendent to Acquisition Agreement

July 25, 2024

Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, and its wholly owned subsidiary, Adivir Inc., have signed a second Amending Agreement with Appili Therapeutics Inc. (TSX: APLI) (OTC: APLIF) regarding its previously announced acquisition agreement. A biopharmaceutical company developing treatments and vaccines for infectious diseases and medical countermeasures, Appili has […]

InvestorNewsBreaks

InvestorNewsBreaks – Evofem Biosciences Inc. (EVFM) Inks Middle East License, Supply Agreement for Proprietary Birth Control Product

July 23, 2024

Evofem Biosciences Inc. (OTCQB: EVFM), a company commercializing innovative products to address unmet needs in women’s sexual and reproductive health, has signed a license and supply agreement for the Middle East rights to Phexxi(R), Evofem’s FDA-approved, hormone-free contraceptive, with private Emirati health care company Pharma 1 Drug Store LLC. Evofem and Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX), Evofem Biosciences (EVFM) Announce Amended, Restates Merger Agreement

July 17, 2024

Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, along with its wholly owned subsidiary Adifem Inc., and Evofem Biosciences Inc. (OTCQB: EVFM) have amended and restated their previously announced merger agreement. According to the announcement, the amended and restated agreement addresses several issues, including preclosing matters such as interim financing needs […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX), Evofem Biosciences (EVFM) Announce Market Partnership with Hello Alpha

June 27, 2024

Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, and Evofem Biosciences Inc. (OTCQB: EVFM) are announcing a new market partnership with Hello Alpha, a telemedicine company with a medical team specifically trained for a woman’s unique needs. Last year, Aditxt entered into a merger agreement with Evofem outlining Aditxt’s plans to acquire […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc.’s (NASDAQ: ADTX) Merger Target Expects ‘Fourth Consecutive Year of Net Sales Growth’

May 15, 2024

Aditxt (NASDAQ: ADTX) recently provided Evofem Biosciences Inc. (OTCQB: EVFM) $1 million in consideration for reinstating and amending the merger agreement, as amended, between the companies. Aditxt agreed to invest an additional $2.5 million in Evofem by July 1, and the companies are working to close the contemplated transaction in the second half of 2024. […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Announces Securities Purchase Agreements, Anticipates Receiving Approximately $4.2M from Placement

May 3, 2024

Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, has entered into securities purchase agreements. The agreements are for the purchase and sale of 4,186 shares of the Company’s Series C-1 Convertible Preferred Stock and 4,186 shares of the Company’s D-1 Preferred Stock, as well as warrants to purchase approximately 1.65 […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Enters Acquisition Agreement to Acquire Biodefense Vaccine Developer

April 2, 2024

Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, has signed a definitive arrangement agreement to acquire Appili Therapeutics Inc. (TSX: APLI) (OTCQX: APLIF). Appili is a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. According to the agreement, Adivir Inc., a wholly owned subsidiary of Aditxt, […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc.’s (NASDAQ: ADTX) Acquisition Target Reports Increased Product Sales, Ongoing Revenue Growth

March 27, 2024

Aditxt (NASDAQ: ADTX) previously entered into a definitive agreement to acquire Evofem Biosciences Inc. (OTCQB: EVFM), which is believed to represent a compelling opportunity to accelerate Evofem’s growth trajectory, as a subsidiary of Aditxt, into a multi-product women’s health franchise. Today Evofem, the company behind Phexxi(R) (lactic acid, citric acid and potassium bitartrate) vaginal gel, […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Potential Acquisition Releases FY 2023 Preliminary Financial Report

February 1, 2024

Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, entered into a definitive agreement with Evofem Biosciences Inc. (OTCQB: EVFM) late last year, and Evofem is reporting its preliminary financial results for 2023, which include record net sales of Phexxi(R), its hormone-free contraceptive gel. According to the report, Phexxi is seeing a […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Acquires Proprietary EEG Portfolio

January 30, 2024

Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, has announced its acquisition of a portfolio of electroencephalography “EEG” brain monitoring technologies and devices formerly owned by Brain Scientific, Inc. The products targeting the neurology monitoring market will be essential in shaping its dynamic landscape for neurological care. “This transaction […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX), Subsidiary Pearsanta Announce Acquisition of MDNA Life Sciences Inc.’s Mitomic(TM) Testing Platform

January 8, 2024

Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, and its subsidiary Pearsanta Inc., have announced the acquisition of MDNA Life Sciences Inc.’s (“MDNA”) proprietary, early-disease and cancer-detection platform. According to the announcement, the acquisition “reinforces Pearsanta’s dedication to enhancing patient outcomes through early-disease detection and the power of precision diagnostics.” […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Secures $6M in Private Placement

January 5, 2024

Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, announced that it has closed its private placement for the purchase and sale of an aggregate of 1,237,114 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $4.85 per […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Regains NASDAQ Compliance, Announces $6M Private Placement

January 2, 2024

Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, has regained compliance with NASDAQ’s minimum stockholders’ equity requirement. The company was notified by NASDAQ regarding the compliance issues, which is subject to a mandatory panel monitor until Dec. 29, 2024. In addition, the company announced that it has entered into definitive […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Announces Definitive Agreement to Acquire Evofem Biosciences Inc.

December 12, 2023

Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, has signed a definitive agreement with Evofem Biosciences Inc. (OTCQB: EVFM), a pioneer in women’s health. The agreement outlines plans for Aditxt to acquire Evofem in a transaction involving the issuance of a combination of common stock and preferred stock as well […]

InvestorNewsBreaks

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Announces Participation at 8th Annual Dawson James Conference

October 6, 2023

Aditxt (NASDAQ: ADTX) is an innovation activation company focused on the discovery, development and deployment of technologies that monitor and modulate the immune system. The company today announced that it will present at the 8th Annual Dawson James Conference on Thursday, Oct. 12, 2023, at the Wyndam Grand Jupiter at Harbourside Place in Jupiter, Florida. […]

No ResultsNo content matches your search/filter.

 

 

 

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(862) 930-1404

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).